140 related articles for article (PubMed ID: 38812492)
1. Clinical efficacy of different androgen deprivation therapies for prostate cancer and evaluation based on dynamic-contrast enhanced magnetic resonance imaging.
Guo W; Li M
Acta Biochim Pol; 2024; 71():12473. PubMed ID: 38812492
[TBL] [Abstract][Full Text] [Related]
2. A comparison of arterial spin labeling perfusion MRI and DCE-MRI in human prostate cancer.
Cai W; Li F; Wang J; Du H; Wang X; Zhang J; Fang J; Jiang X
NMR Biomed; 2014 Jul; 27(7):817-25. PubMed ID: 24809332
[TBL] [Abstract][Full Text] [Related]
3. Preoperative histogram parameters of dynamic contrast-enhanced MRI as a potential imaging biomarker for assessing the expression of Ki-67 in prostate cancer.
Zhang Y; Li Z; Gao C; Shen J; Chen M; Liu Y; Cao Z; Pang P; Cui F; Xu M
Cancer Med; 2021 Jul; 10(13):4240-4249. PubMed ID: 34117733
[TBL] [Abstract][Full Text] [Related]
4. Differential diagnosis of prostate cancer and noncancerous tissue in the peripheral zone and central gland using the quantitative parameters of DCE-MRI: A meta-analysis.
Gao P; Shi C; Zhao L; Zhou Q; Luo L
Medicine (Baltimore); 2016 Dec; 95(52):e5715. PubMed ID: 28033274
[TBL] [Abstract][Full Text] [Related]
5. DCE-MRI of the prostate using shutter-speed vs. Tofts model for tumor characterization and assessment of aggressiveness.
Hectors SJ; Besa C; Wagner M; Jajamovich GH; Haines GK; Lewis S; Tewari A; Rastinehad A; Huang W; Taouli B
J Magn Reson Imaging; 2017 Sep; 46(3):837-849. PubMed ID: 28092414
[TBL] [Abstract][Full Text] [Related]
6. Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging in the activity staging of terminal ileum Crohn's disease.
Wu YC; Xiao ZB; Lin XH; Zheng XY; Cao DR; Zhang ZS
World J Gastroenterol; 2020 Oct; 26(39):6057-6073. PubMed ID: 33132655
[TBL] [Abstract][Full Text] [Related]
7. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for pretreatment prediction of neoadjuvant chemotherapy response in locally advanced hypopharyngeal cancer.
Guo W; Zhang Y; Luo D; Yuan H
Br J Radiol; 2020 Nov; 93(1115):20200751. PubMed ID: 32915647
[No Abstract] [Full Text] [Related]
8. Application evaluation of DCE-MRI combined with quantitative analysis of DWI for the diagnosis of prostate cancer.
Ma XZ; Lv K; Sheng JL; Yu YX; Pang PP; Xu MS; Wang SW
Oncol Lett; 2019 Mar; 17(3):3077-3084. PubMed ID: 30867737
[TBL] [Abstract][Full Text] [Related]
9. A direct comparison of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer detection and prediction of aggressiveness.
Baur ADJ; Schwabe J; Rogasch J; Maxeiner A; Penzkofer T; Stephan C; Rudl M; Hamm B; Jung EM; Fischer T
Eur Radiol; 2018 May; 28(5):1949-1960. PubMed ID: 29238867
[TBL] [Abstract][Full Text] [Related]
10. The Assessment of Prostate Cancer Aggressiveness Using a Combination of Quantitative Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Zhu G; Luo J; Ouyang Z; Cheng Z; Deng Y; Guan Y; Du G; Zhao F
Cancer Manag Res; 2021; 13():5287-5295. PubMed ID: 34239327
[TBL] [Abstract][Full Text] [Related]
11. Comparison of diffusion kurtosis imaging and dynamic contrast enhanced MRI in prediction of prognostic factors and molecular subtypes in patients with breast cancer.
Wang W; Lv S; Xun J; Wang L; Zhao F; Wang J; Zhou Z; Chen Y; Sun Z; Zhu L
Eur J Radiol; 2022 Sep; 154():110392. PubMed ID: 35679701
[TBL] [Abstract][Full Text] [Related]
12. Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI.
Hötker AM; Mazaheri Y; Zheng J; Moskowitz CS; Berkowitz J; Lantos JE; Pei X; Zelefsky MJ; Hricak H; Akin O
Eur Radiol; 2015 Sep; 25(9):2665-72. PubMed ID: 25820537
[TBL] [Abstract][Full Text] [Related]
13. Dynamic contrast-enhanced (DCE) MR imaging: the role of qualitative and quantitative parameters for evaluating prostate tumors stratified by Gleason score and PI-RADS v2.
Afshari Mirak S; Mohammadian Bajgiran A; Sung K; Asvadi NH; Markovic D; Felker ER; Lu D; Sisk A; Reiter RE; Raman SS
Abdom Radiol (NY); 2020 Jul; 45(7):2225-2234. PubMed ID: 31549211
[TBL] [Abstract][Full Text] [Related]
14. Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T.
Vos EK; Litjens GJ; Kobus T; Hambrock T; Hulsbergen-van de Kaa CA; Barentsz JO; Huisman HJ; Scheenen TW
Eur Urol; 2013 Sep; 64(3):448-55. PubMed ID: 23751135
[TBL] [Abstract][Full Text] [Related]
15. Application of Dynamic Enhanced Magnetic Resonance Imaging Texture Analysis Combined with ADCs in Predicting Pelvic Lymph Metastasis of Prostate Cancer.
Yao L; Ding J; Li X; Yang J; Chen Z; Jia C; Duan Q
Arch Esp Urol; 2023 Aug; 76(6):383-388. PubMed ID: 37681328
[TBL] [Abstract][Full Text] [Related]
16. Quantitative contrast-enhanced perfusion kinetics in multiparametric MRI in differentiating prostate cancer from chronic prostatitis: results from a pilot study.
Sureka B; Elhence P; Khera PS; Choudhary GR; Pandey H; Garg PK; Yadav K; Goel A
Br J Radiol; 2019 Aug; 92(1100):20190181. PubMed ID: 31184934
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Dispersion MRI for Improved Prostate Cancer Diagnosis in a Multicenter Study.
Turco S; Lavini C; Heijmink S; Barentsz J; Wijkstra H; Mischi M
AJR Am J Roentgenol; 2018 Nov; 211(5):W242-W251. PubMed ID: 30346837
[TBL] [Abstract][Full Text] [Related]
18. Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology.
Sun C; Chatterjee A; Yousuf A; Antic T; Eggener S; Karczmar GS; Oto A
AJR Am J Roentgenol; 2019 Feb; 212(2):351-356. PubMed ID: 30540213
[TBL] [Abstract][Full Text] [Related]
19. Comparison of double inversion recovery magnetic resonance imaging (DIR-MRI) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in detection of prostate cancer: A pilot study.
Onwuharine EN; Clark AJ
Radiography (Lond); 2020 Aug; 26(3):234-239. PubMed ID: 32052752
[TBL] [Abstract][Full Text] [Related]
20. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
Schulman C; Cornel E; Matveev V; Tammela TL; Schraml J; Bensadoun H; Warnack W; Persad R; Salagierski M; Gómez Veiga F; Baskin-Bey E; López B; Tombal B
Eur Urol; 2016 Apr; 69(4):720-727. PubMed ID: 26520703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
